drugset / Trial / NCT01080248
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
To determine the response rate and survival of gemcitabine and pazopanib in patients with metastatic pancreatic cancer.
Timeline
- Start
- 2010-08
- Primary completion
- 2010-12
- Completion
- 2011-10
Outcome
Outcome not reported
Stopped: “Closed due to delay by GSK”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |